<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>The Nevada National Board Professional Learning Institute | Kok | Activity</title>
	<link>http://www.nationalboardinstitute.com/members/curveslice4/activity/</link>
	<atom:link href="http://www.nationalboardinstitute.com/members/curveslice4/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Kok.</description>
	<lastBuildDate>Fri, 23 May 2025 17:06:54 -0700</lastBuildDate>
	<generator>https://buddypress.org/?v=9.1.1</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">50642ed9fc10e868d5f2782a9ebed3ba</guid>
				<title>Kok posted an update: In conclusion, this study provided the first evidence for [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/41981/</link>
				<pubDate>Sat, 08 Feb 2025 11:46:12 -0800</pubDate>

									<content:encoded><![CDATA[<p>In conclusion, this study provided the first evidence for the involvement of the hypothalamus in the promotion effect of SNS on OTM. This work could provide a novel theoretical and experimental basis for further understanding of the molecular mechanism of OTM.</p>
<p> This study aimed to predict the presence and mechanism of busulfan drug-drug&hellip;<span class="activity-read-more" id="activity-read-more-41981"><a href="http://www.nationalboardinstitute.com/activity/p/41981/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">d5bf2a402ac4e27c4657033c60533458</guid>
				<title>Kok posted an update: ), although movement data and the discovery of a [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/40211/</link>
				<pubDate>Thu, 06 Feb 2025 14:30:58 -0800</pubDate>

									<content:encoded><![CDATA[<p>), although movement data and the discovery of a Malaysia-clade NiV strain in eastern Bangladesh suggest connectivity with bats east of Bangladesh. These data suggest that discrete multiannual local epizootics in bat populations contribute to the sporadic nature of NiV outbreaks in South Asia. At the same time, the broad spatial and temporal&hellip;<span class="activity-read-more" id="activity-read-more-40211"><a href="http://www.nationalboardinstitute.com/activity/p/40211/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">f19121d127315b970a47cdabcc04ec0c</guid>
				<title>Kok posted an update: Our data suggest this phenomenon occurs through a mechanism [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/38507/</link>
				<pubDate>Tue, 04 Feb 2025 11:47:03 -0800</pubDate>

									<content:encoded><![CDATA[<p>Our data suggest this phenomenon occurs through a mechanism that differs from PTS-transport of oligosaccharides generated from either degradation or chitinase-mediated hydrolysis of the polymer. Importantly, an indication that chitin can repress virulence expression of a constitutively active PrfA∗ mutant is shown, possibly mediated via a p&hellip;<span class="activity-read-more" id="activity-read-more-38507"><a href="http://www.nationalboardinstitute.com/activity/p/38507/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">901e94271fa3dbe31aca5f1502980bc6</guid>
				<title>Kok posted an update: MAD2L1 was identified as a direct target of miR-139-5p in [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/36723/</link>
				<pubDate>Sun, 02 Feb 2025 11:45:57 -0800</pubDate>

									<content:encoded><![CDATA[<p>MAD2L1 was identified as a direct target of miR-139-5p in LUAD. Besides, the inhibitory effect of miR-139-5p overexpression on LUAD cell proliferation, migration, and invasion was attenuated by overexpressing MAD2L1.</p>
<p> Our study suggests that miR-139-5p is lowly expressed in LUAD cells and inhibits LUAD cell proliferation, migration, and&hellip;<span class="activity-read-more" id="activity-read-more-36723"><a href="http://www.nationalboardinstitute.com/activity/p/36723/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">b83c0d7e640d694519cc2de89b4b1beb</guid>
				<title>Kok posted an update: Breast cancer is the second most commonly identified cancer [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/34138/</link>
				<pubDate>Thu, 30 Jan 2025 11:54:35 -0800</pubDate>

									<content:encoded><![CDATA[<p>Breast cancer is the second most commonly identified cancer in women in the United States after skin cancer. The past few years have seen a substantial increase in breast cancer awareness campaigns and active research in fields of diagnosis and targeted therapy. These factors have led to a better mechanistic understanding of the disease, detection&hellip;<span class="activity-read-more" id="activity-read-more-34138"><a href="http://www.nationalboardinstitute.com/activity/p/34138/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">dc8a2363ea13f9b3aaca899641a3cbd0</guid>
				<title>Kok posted an update: While the effectiveness of baricitinib was similar [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/32254/</link>
				<pubDate>Tue, 28 Jan 2025 18:09:22 -0800</pubDate>

									<content:encoded><![CDATA[<p>While the effectiveness of baricitinib was similar regardless of whether patients had a history of only one or multiple targeted DMARDs use, patients with previous use of non-TNF inhibitors or JAK inhibitors showed lower rates of improvement in DAS28-CRP. The overall retention rate for baricitinib was 86.5% at 24 weeks, as estimated by&hellip;<span class="activity-read-more" id="activity-read-more-32254"><a href="http://www.nationalboardinstitute.com/activity/p/32254/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">a0849b225292b5a6c3a120684755c997</guid>
				<title>Kok became a registered member</title>
				<link>http://www.nationalboardinstitute.com/activity/p/32238/</link>
				<pubDate>Tue, 28 Jan 2025 18:07:27 -0800</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>